Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03029832
Title A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Genentech, Inc.

transitional cell carcinoma



Atezolizumab + MOXR0916

Age Groups: senior | adult
Covered Countries USA | CAN | BEL

No variant requirements are available.